Predictive Factors for Submacular Hemorrhage in Age-related Macular Degeneration: A Retrospective Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Little is known about the major risk factors for submacular hemorrhage (SMH). This study aimed to evaluate the factors associated with SMH in patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy receiving three consecutive loading doses of intravitreal aflibercept or ranibizumab injections. Methods: This retrospective cross-sectional study included 48 patients diagnosed with nAMD and polypoidal choroidal vasculopathy who completed three loading doses under a treat-and-extend regimen. Patients were divided into the SMH group and the non-SMH group (age- and sex-matched without SMH), with 24 patients in each group. Intravitreal injections, agents, and optical coherence tomography (OCT) features were compared. Results: In the SMH group, SMH occurred approximately 3.29 years after post-nAMD diagnosis. The non-SMH group received more intravitreal injections of aflibercept and brolucizumab during the follow-up period after the initial loading phase. The SMH group exhibited a higher prevalence of serous/hemorrhagic pigment epithelial detachments (PEDs) at the last visit before SMH occurrence compared to the non-SMH group. Patients with a PED increase in the past two visits showed a higher tendency in the SMH group. No other OCT features significantly correlated with SMH development. Conclusions: The presence of serous/hemorrhagic PEDs may indicate a higher risk of SMH, and eyes with these features should be closely monitored to prevent sudden and devastating visual loss caused by SMH.
Abstract
Purpose: Little is known about the major risk factors for submacular hemorrhage (SMH). This study aimed to evaluate the factors associated with SMH in patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy receiving three consecutive loading doses of intravitreal aflibercept or ranibizumab injections. Methods: This retrospective cross-sectional study included 48 patients diagnosed with nAMD and polypoidal choroidal vasculopathy who completed three loading doses under a treat-and-extend regimen. Patients were divided into the SMH group and the non-SMH group (age- and sex-matched without SMH), with 24 patients in each group. Intravitreal injections, agents, and optical coherence tomography (OCT) features were compared. Results: In the SMH group, SMH occurred approximately 3.29 years after post-nAMD diagnosis. The non-SMH group received more intravitreal injections of aflibercept and brolucizumab during the follow-up period after the initial loading phase. The SMH group exhibited a higher prevalence of serous/hemorrhagic pigment epithelial detachments (PEDs) at the last visit before SMH occurrence compared to the non-SMH group. Patients with a PED increase in the past two visits showed a higher tendency in the SMH group. No other OCT features significantly correlated with SMH development. Conclusions: The presence of serous/hemorrhagic PEDs may indicate a higher risk of SMH, and eyes with these features should be closely monitored to prevent sudden and devastating visual loss caused by SMH.
참고문헌 (23)
- Stanescu-Segall D, "Submacular hemorrhage in neovascular age-related macular degeneration : a synthesis of the literature", Surv Ophthalmol, 61, pp.18~32 (2016)
- Hochman MA, "Pathophysiology and management of subretinal hemorrhage", Surv Ophthalmol, 42, pp.195~213 (1997)
- Kunavisarut P, "Submacular hemorrhage : visual outcomes and prognostic factors", Asia Pac J Ophthalmol(Phila), 7, pp.109~113 (2018)
- Steel DH, "Submacular haemorrhages associated with neovascular age-related macular degeneration", Br J Ophthalmol, 95, pp.1051~1057 (2011)
- Chang YS, "Development of submacular hemorrhage in neovascular age-related macular degeneration : influence on visual prognosis in a clinical setting", Korean J Ophthalmol, 32, pp.361~368 (2018)
- Scupola A, "Natural history of macular subretinal hemorrhage in age-related macular degeneration", Ophthalmologica, 213, pp.97~102 (1999)
- Ugurtay O, "Real life data of treat and extend intravitreal ranibizumab and aflibercept therapy in wet age-related macular degeneration patients : 3-year results", Korean J Ophthalmol, 35, pp.280~286 (2021)
- Brown DM, "R anibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Heier JS, "Intravitreal aflibercept(VEGF trap-eye)in wet age-related macular degeneration", Ophthalmology, 119, pp.2537~2548 (2012)
- Schmidt-Erfurth U, "Intravitreal af libercept injection for neovascular age-related macular degeneration : ninety-six-week results of the VIEW studies", Ophthalmology, 121, pp.193~201 (2014)
- Kim J, "Short-term efficacy and safety of intravitreal brolucizumab injection for treatment-naïve exudate age-related macular degeneration : a multicenter study", Korean J Ophthalmol, 37, pp.365~372 (2023)
- Berrocal MH, "Variations in the clinical course of submacular hemorrhage", Am J Ophthalmol, 122, pp.486~493 (1996)
- Kang HG, "Clinical characteristics, risk factors, and surgical outcomes of secondary macular hole after vitrectomy", Sci Rep, 9, pp.19535~ (2019)
- Gabrielle PH, "Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry", Acta Ophthalmol, 100, pp.e1569~e1578 (2022)
- Cho JH, "Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy", Am J Ophthalmol, 169, pp.79~88 (2016)
- Chung YR, "Hypertension as a risk factor for recurrent subretinal hemorrhage in polypoidal choroidal vasculopathy", Can J Ophthalmol, 51, pp.348~353 (2016)
- Fung AE, "An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration", Am J Ophthalmol, 143, pp.566~583 (2007)
- Gemenetzi M, "A systematic review of the treat and extend treatment regimen with anti-VEGF agents for neovascular age-related macular degeneration", Ophthalmol Ther, 6, pp.79~92 (2017)
- Mehta A, "Associations and outcomes of patients with submacular hemorrhage secondary to age-related macular degeneration in the IVAN trial", Am J Ophthalmol, 236, pp.89~98 (2022)
- Krishnan R, "Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization", Clin Exp Ophthalmol, 37, pp.384~388 (2009)
- Cho HJ, "Hemorrhagic complications after intravitreal ranibizumab injection for polypoidal choroidal vasculopathy", Can J Ophthalmol, 47, pp.170~175 (2012)
- Khoo C, "Submacular hemorrhage following aflibercept intravitreal injection : a report of two cases", Cureus, 14, pp.e27255~ (2022)